Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Lawrence Rettenmaier (NPI 1679688626)

Field	Value
Entity Type	Individual
Organization	Lawrence Rettenmaier
Address	8421 Plum Dr
City	Urbandale
State	IA
ZIP	50322
Taxonomy	Rheumatology Physician
NPI Enumerated	August 20, 2006

Payer Source	Total Paid
Medicare	$951.3K
Medicaid	$0

Key Findings

This provider’s billing is effectively single‑payer: lifetime Medicare revenue is $951.3K while Medicaid shows none (no Medicaid billing on file), indicating the practice derives virtually all public‑payer volume from Medicare and has no recorded Medicaid activity. That concentration implies payer mix and network considerations should be evaluated primarily against Medicare reimbursement and utilization patterns rather than dual‑payer strategies.

Revenue concentration is high among biologic drug administration codes: the precomputed top‑3 Medicare codes account for 53.2% of total Medicare revenue, with J0717 generating $199.2K (21.4%), J0129 generating $168.3K (18.1%), and J1745 generating $127.9K (13.7%). This concentration shows the practice’s revenue is driven primarily by high‑cost injectable biologics rather than by a broad portfolio of office visit fees.

Business/service‑line signals are consistent with an infusion/biologics‑focused rheumatology practice: dominant codes are J0717, J0129, and J1745 (certolizumab, abatacept, infliximab), and the presence of infusion administration codes such as 96413, 96401, 96415, and 96365 indicates in‑office infusion/administration capacity. Combined with frequent lab codes (e.g., 82565, 84450, 84460) and DXA imaging (77080, 77089), the mix suggests ongoing monitoring and in‑clinic procedures typical for long‑term biologic management in rheumatology.

Competitive standing on drug codes is mixed: J0717 ranks #406 of 848 providers nationally (52th percentile) and is described as typical, unremarkable volume for this code, J0129 ranks #899 of 1221 (26th percentile) and is also typical, unremarkable volume, while J1745 ranks #380 of 1352 (72th percentile) with typical, unremarkable volume. In plain terms, this provider is not a dominant national outlier for these biologics but does sit at mid‑range to upper‑mid range on some drug lines, reflecting a modest national footprint for individually reported drug codes.

Clinical throughput for office visits and basic procedures is notable: 99213 appears at 781 claims and $45.3K revenue and ranks #11287 of 457151 providers nationally (98th percentile), explicitly labeled as notably above typical national volume for this code. High percentile rankings for routine specimen collection (36415, 94th percentile) and several common lab tests (e.g., 82565 at the 96th percentile) further indicate above‑typical throughput of outpatient visits and ancillary services supporting ongoing chronic care.

Operational risk and sensitivity: because over half of Medicare revenue (53.2%) is concentrated in three biologic drug codes, the practice’s revenue profile is sensitive to changes in drug reimbursement, utilization patterns, or site‑of‑care payment policies for these specific agents. Payers and financial analysts should view this as a strategic dependency on billed biologics and on in‑office administration capacity.

Tenure and market presence: the NPI was enumerated on 2006-08-20 (~20 years ago), indicating long‑standing enrollment and potential continuity of care in the market. This tenure supports the observed steady volume of chronic care services and recurring biologic administration reflected in the claims mix.

Practice-level implications for network and contract strategy: given the lack of Medicaid billing and a Medicare‑centric revenue base of $951.3K, contract negotiations and utilization management should be focused on Medicare fee schedules, drug reimbursement policy, and infusion service rates rather than Medicaid program terms. Payers considering network alignment should also account for the provider’s above‑typical office visit and lab throughput when modeling utilization and downstream monitoring needs.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

45 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	49,800	$1	$199.2K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	4,950	$30	$168.3K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	4,920	$30	$127.9K
J3262	Injection, tocilizumab, 1 mg	27,240	$1	$109K
J3111	Injection, romosozumab-aqqg, 1 mg	13,020	$10	$104.2K
J0897	Injection, denosumab, 1 mg	4,200	$20	$75.6K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	780	$60	$45.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	280	$90	$25.9K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	280	$50	$15.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	130	$80	$10.7K

Showing 1–10 of 45

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 45 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Lawrence Rettenmaier — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

45 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J3262	6	10	35,440	$1	$233.1K
J0129	11	20	5,950	$30	$218.3K
J3111	9	20	12,180	$10	$112K
J0717	1	20	23,500	$1	$93.9K
J1745	4	20	3,460	$30	$92.3K
J0897	51	190	1,920	$20	$74.1K
96413	30	80	210	$90	$24K
99214	1,983	4,690	100	$70	$14.4K
99490	184	330	130	$40	$9K
99213	75	4,740	100	$50	$8K

Showing 1–10 of 45

Nearby Providers

Other providers in the same ZIP code as Lawrence Rettenmaier, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mosaic	IA	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$177.4M
The Respite Connection, Inc.	IA	Community/Behavioral Health Agency	$0	$38.1M
Unitypoint At Home	IA	Durable Medical Equipment & Medical Supplies	$0	$16.5M
Unitypoint At Home	IA	Home Infusion Therapy Pharmacy	$0	$15.4M
New Beginnings Counseling Service, LLC	IA	Community/Behavioral Health Agency	$0	$6.3M
A-1 Iowa Dental PLLC	IA	Dentist	$0	$5.4M
Urbandale Community School District	IA	Local Education Agency (LEA)	$0	$4.4M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$3.9M
Acs Medical LLC	IA	Durable Medical Equipment & Medical Supplies	$0	$3.6M
Wellserve Health, Inc.	IA	Community/Behavioral Health Agency	$0	$2.8M

Lawrence Rettenmaier — Billing Profile & Reimbursement Data

Sign up for Lawrence Rettenmaier — Billing Profile & Reimbursement Data policy alerts

Lawrence Rettenmaier — Billing Profile & Reimbursement Data

Sign up for Lawrence Rettenmaier — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Nearby Providers

Frequently Asked Questions

References